KRTX - Karuna Therapeutics EPS in-line

Karuna Therapeutics (KRTX): Q1 GAAP EPS of -$1.10 in-line.Cash, cash equivalents and investment of $571.3M.“This year is off to a very productive start, with the advancement of our early- and late-stage clinical programs, most notably the initiation and ongoing enrollment of three Phase 3 trials in our EMERGENT program, the clinical program evaluating KarXT, our lead product candidate, in schizophrenia,” said Steve Paul, M.D., chief executive officer, president and chairman. “We believe KarXT represents a major advance in the treatment of neuropsychiatric conditions, such as schizophrenia and dementia-related psychosis, where symptoms of psychosis are prominent and disabling. We look forward to furthering our journey to improve the lives of those living with these conditions.”Press Release

For further details see:

Karuna Therapeutics EPS in-line